MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference
25 February 2020 - 10:25AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with diseases such as diabetes
and pulmonary arterial hypertension, announced today that it will
be featured as a presenting company at the 9th Annual SVB Leerink
Global Healthcare Conference on Thursday, February 27, 2020 at 9:30
am (ET) at the Lotte New York Palace Hotel in New York, NY.
Presenting from the Company will be its Chief Executive Officer,
Michael Castagna, PharmD. Interested parties can access a link to
the live webcast of the presentation from the News & Events
section of the Company's website at http://www.mannkindcorp.com.
The webcast replay will remain available for 14 days following the
live presentation.
About MannKind
CorporationMannKind Corporation (NASDAQ:MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently commercializing
Afrezza® (insulin human) Inhalation Powder, the Company's first
FDA-approved product and the only inhaled ultra rapid-acting
mealtime insulin in the United States, where it is available by
prescription from pharmacies nationwide. MannKind is headquartered
in Westlake Village, California, and has a state-of-the art
manufacturing facility in Danbury, Connecticut. The Company also
employs field sales and medical representatives across the U.S. For
further information, visit www.mannkindcorp.com.
Company
Contact:818-661-5000ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2024 to May 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From May 2023 to May 2024